J Paul Simons

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4792906/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 2021, 12, 7112.	5.8	13
2	Novel defect in phosphatidylinositol 4â€kinase type 2â€alpha (<scp><i>PI4K2A</i></scp>) at the membraneâ€enzyme interface is associated with metabolic cutis laxa. Journal of Inherited Metabolic Disease, 2020, 43, 1382-1391.	1.7	7
3	Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. Molecular Therapy, 2019, 27, 2111-2122.	3.7	120
4	Amyloid β synaptotoxicity is Wntâ€PCP dependent and blocked by fasudil. Alzheimer's and Dementia, 2018, 14, 306-317.	0.4	81
5	A role for APP in Wnt signalling links synapse loss with β-amyloid production. Translational Psychiatry, 2018, 8, 179.	2.4	74
6	A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo. Scientific Reports, 2017, 7, 46711.	1.6	18
7	Type II PI4-kinases control Weibel-Palade body biogenesis and von Willebrand factor structure in Human endothelial cells. Journal of Cell Science, 2016, 129, 2096-105.	1.2	17
8	The effects of short-term JNK inhibition on the survival and growth of aged sympathetic neurons. Neurobiology of Aging, 2016, 46, 138-148.	1.5	1
9	Amyloid persistence in decellularized liver: biochemical and histopathological characterization. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 1-7.	1.4	25
10	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits <i>in vivo</i> . Open Biology, 2016, 6, 150202.	1.5	21
11	Reducing β-Amyloid by Inhibition of BACE1: How Low Should You Go?. Biological Psychiatry, 2015, 77, 683-684.	0.7	3
12	Class I Major Histocompatibility Complex, the Trojan Horse for Secretion of Amyloidogenic β2-Microglobulin. Journal of Biological Chemistry, 2014, 289, 3318-3327.	1.6	22
13	Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway. Molecular Psychiatry, 2014, 19, 88-98.	4.1	197
14	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 2014, 29, 1476-1485.	2.2	384
15	Câ€reactive protein is essential for innate resistance to pneumococcal infection. Immunology, 2014, 142, 414-420.	2.0	51
16	Pathogenetic mechanisms of amyloid A amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16115-16120.	3.3	79
17	Exon Skipping of Hepatic APOB Pre-mRNA With Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo. Molecular Therapy, 2013, 21, 602-609.	3.7	26
18	Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 93-98.	1.4	7

J PAUL SIMONS

#	Article	IF	CITATIONS
19	Targeted In Situ Gene Correction of Dysfunctional <i>APOE</i> Alleles to Produce Atheroprotective Plasma ApoE3 Protein. Cardiology Research and Practice, 2012, 2012, 1-16.	0.5	9
20	Oligonucleotideâ€mediated gene editing is underestimated in cells expressing mutated green fluorescent protein and is positively associated with target protein expression. Journal of Gene Medicine, 2012, 14, 109-119.	1.4	2
21	Oligonucleotide-directed gene-editing technology: mechanisms and future prospects. Expert Opinion on Biological Therapy, 2012, 12, 329-342.	1.4	27
22	Screening for mutations in the phosphatidylinositol 4-kinase 2-alpha gene in autosomal recessive hereditary spastic paraplegia. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 148-149.	2.3	6
23	Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle. Metabolism: Clinical and Experimental, 2011, 60, 491-498.	1.5	5
24	Equilibrium contrast CMR for the detection of amyloidosis in mice. Journal of Cardiovascular Magnetic Resonance, 2011, 13, .	1.6	2
25	Loss of phosphatidylinositol 4-kinase 2α activity causes late onset degeneration of spinal cord axons. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11535-11539.	3.3	77
26	Validation of oligonucleotide-mediated gene editing. Gene Therapy, 2009, 16, 824-826.	2.3	7
27	Overexpression of 5â€HT _{2C} receptors in forebrain leads to elevated anxiety and hypoactivity. European Journal of Neuroscience, 2009, 30, 299-306.	1.2	39
28	Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice. Atherosclerosis, 2009, 204, 121-126.	0.4	13
29	Notch controls embryonic Schwann cell differentiation, postnatal myelination and adult plasticity. Nature Neuroscience, 2009, 12, 839-847.	7.1	285
30	Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. European Journal of Neuroscience, 2008, 27, 2103-2114.	1.2	95
31	Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. European Journal of Neuroscience, 2008, 28, 1940-1940.	1.2	2
32	Human Apolipoprotein E Expression from Mouse Skeletal Muscle by Electrotransfer of Nonviral DNA (Plasmid) and Pseudotyped Recombinant Adeno-Associated Virus (AAV2/7). Human Gene Therapy, 2008, 19, 569-578.	1.4	14
33	The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. FEBS Letters, 2007, 581, 2727-2732.	1.3	86
34	ProNGF, Sortilin, and Ageâ€related Neurodegeneration. Annals of the New York Academy of Sciences, 2007, 1119, 208-215.	1.8	62
35	The expression and alternative splicing of alpha-neurexins during Xenopus development. International Journal of Developmental Biology, 2006, 50, 39-46.	0.3	21
36	Correction of the Neuropathogenic Human Apolipoprotein E4 (<i>APOE4</i>) Gene to <i>APOE3</i> in Vitro Using Synthetic RNA/DNA Oligonucleotides (Chimeraplasts). Journal of Molecular Neuroscience, 2005, 25, 095-104.	1.1	10

J PAUL SIMONS

#	Article	IF	CITATIONS
37	Lack of RNA-DNA oligonucleotide (chimeraplast) mutagenic activity in mouse embryos. Molecular Reproduction and Development, 2005, 71, 140-144.	1.0	4
38	Differential spatio-temporal expression of alpha-dystrobrevin-1 during mouse development. Gene Expression Patterns, 2004, 4, 583-593.	0.3	22
39	Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Development Genes and Evolution, 2001, 211, 161-171.	0.4	104
40	The dangers of DNA vaccination. Nature Medicine, 1999, 5, 126-126.	15.2	6
41	The Secretory Pathway for Milk Protein Secretion and Its Regulation. , 1995, , 253-263.		2
42	Manipulation of the Repertoire of Digestive Enzymes Secreted into the Gastrointestinal Tract of Transgenic Mice. Bio/technology, 1993, 11, 376-379.	1.9	61
43	Targeting expression to the mammary gland: intronic sequences can enhance the efficiency of gene expression in transgenic mice. Transgenic Research, 1991, 1, 3-13.	1.3	127
44	Modification of Milk by Gene Transfer. , 1989, , 124-132.		0
45	Gene Transfer into Sheep. Nature Biotechnology, 1988, 6, 179-183.	9.4	83
46	Alteration of the quality of milk by expression of sheep β-lactoglobulin in transgenic mice. Nature, 1987, 328, 530-532.	13.7	281
47	Linkage of adult α- and β-globin genes in X. laevis and gene duplication by tetraploidization. Cell, 1980, 21, 555-564.	13.5	202